Search academic texts

Information × Registration Number 0211U005224, 0107U012353 , R & D reports Title Elaboration and preclinical study of a soluble preparation 1-(o-chlorophenyl)-1-(p'- chlorophenyl)-2,2-di-chloroethane (o,p'- DDD) for the treatment of Cushing's disease and adrenal carcinomas. popup.stage_title Head Balion Yaroslav Grigorovisch; Komisarenko Igor Vasylevysch, Registration Date 04-03-2011 Organization State Institution "V.P. Komisarenko Institute of Endocrinology and Metabolism оf the Academy of Medical Scienses of Ukraine" popup.description2 Object:Preparation 1-(o-chlorophenyl)-1-(p'- chlorophenyl)-2,2-di-chloroethane (o,p'- DDD). Aim of stady: to obtain a soluble form of an adrenocorticolytic preparation o,p'-DDD; performance of preclinical investigations. Methods: Chemical, physico-chemical, biochemical methods. Theoretical and practical results: an injectable form of o,p'-DDD has been created: a 5% solution in a mix of solvents (70% of propylene glycol, 20% of ethanol, 10% of N,N-dimethylacetamide). Investigations conducted on dogs have shown that this form does not cause vascular embolism; LD50 of a 5% solution for injections was about 460 mg/kg, i.e. this form is safe for therapeutic use. A study of adrenocorticolytic activity of this o,p'-DDD form has shown that already after three injections of 10 ml of a 5% solution to dogs (a total of 1.5 g of active substance) after 24 hours resulted in nearly a fourfold decrease in 11-hydroxycorticosteroid level. Such a 11-HOCS level in dogs was reached in case of per os use of 20-25 g of o,p'-DDD. The term of stability of sterilized injectable form was studied within 2010. A quantitative determination of preparation was carried out by liquid chromatography, and its individuality using UV-spectroscopy. According to these data, the drug remains stable for a period of two years. Novelty: For the first time, a soluble form of preparation 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) has been obtained and studied. Efficacy of the method: This drug will improve the efficacy of treatment of Cushing's disease and adrenocortical tumours. Degree of introduction: Patent, articles. Sphere of use: Endocrinology, oncology. Product Description popup.authors Бальон Ярослав Григорович Вакуленок Лідія Іванівна Сімуров Олексій Володимирович Танцюра Леся Володимирівна Точілкіна Лідія Михайлівна popup.nrat_date 2020-04-02 Close